Skip to main content

Table 3 Impact of pS383/392-ATG4B expression levels on overall survival by the different demographic and clinicopathologic factors with colorectal cancer

From: ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer

Variable

 

No. (%)

CHR (95% CI)

p value*

AHR (95% CI)

p value †

Sex

      

 Female

Low

35 (74.5)

1.00

 

1.00

 

High

12 (25.5)

1.98 (0.82–4.78)

0.127

1.03 (0.37–2.90)

0.953a

 Male

Low

47 (66.2)

1.00

 

1.00

 

High

24 (33.8)

4.04 (1.94–8.40)

< 0.001

3.72 (1.70–8.14)

0.001 a

Age, years

      

 ≦ 60

Low

29 (64.4)

1.00

 

1.00

 

High

16 (35.6)

3.73 (1.49–9.35)

0.005

2.30 (0.79–6.65)

0.125a

 >60

Low

53 (72.6)

1.00

 

1.00

 

High

20 (27.4)

2.74 (1.36–5.49)

0.005

2.43 (1.14–5.21)

0.022 a

Cell differentiation

      

 Well

Low

3 (75.0)

1.00

 

1.00

 

High

1 (25.0)

434.45 (0.00-8.954E + 12)

0.616

92.86 (0.00-13265331940)

0.636b

 Moderate, poor

Low

79 (69.3)

1.00

 

1.00

 

High

35 (30.7)

2.93 (1.67–5.13)

< 0.001

2.26 (1.27-4.00)

0.005 b

AJCC pathological stage

      

 I, II

Low

50 (89.3)

1.00

 

1.00

 

High

6 (10.7)

4.74 (1.53–14.71)

0.007

4.81 (1.53–15.09)

0.007 c

 III, IV

Low

32 (51.6)

1.00

 

1.00

 

High

30 (48.4)

2.12 (1.06–4.24)

0.034

2.07 (1.03–4.16)

0.042 c

T classification

      

 T1, T2

Low

21 (100.0)

1.00

 

1.00

 

High

0 (0.0)

Incalculable

 

Incalculable

 

 T3, T4

Low

61 (62.9)

1.00

 

1.00

 

High

36 (37.1)

2.82 (1.57–5.07)

0.001

2.86 (1.51–5.42)

0.001 d

N classification

      

 N0

Low

55 (85.9)

1.00

 

1.00

 

High

9 (14.1)

5.38 (2.17–13.36)

< 0.001

5.32 (1.98–14.27)

0.001 e

 N1, N2

Low

27 (50.0)

1.00

 

1.00

 

High

27 (50.0)

2.19 (1.01–4.76)

0.047

2.12 (0.97–4.64)

0.060e

Postoperative RT

      

 No

Low

79 (71.8)

1.00

 

1.00

 

High

31 (28.2)

3.90 (2.22–6.87)

< 0.001

3.02 (1.63–5.62)

< 0.001 a

 Yes

Low

3 (37.5)

1.00

 

1.00

 

High

5 (62.5)

0.35 (0.02–6.15)

0.470

14.53 (0.00-326310532.6)

0.757a

  1. Abbreviations: SCC, squamous cell carcinoma; CHR, crude hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio; AJCC, American Joint Committee on Cancer; RT, radiotherapy.
  2. *p values were estimated by Cox’s regression.
  3. † p values were estimated by multivariate Cox’s regression.
  4. a Adjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs. stage I + II).
  5. b Adjusted for AJCC pathological stage (stage III + IV vs. stage I + II).
  6. c Adjusted for cell differentiation (moderate + poor vs. well).
  7. d Adjusted for cell differentiation (moderate + poor vs. well) and N classification (N1, N2 vs. N0).
  8. e Adjusted for cell differentiation (moderate + poor vs. well) and T classification (T3, T4 vs. T1 + T2).